Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of
hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical …

Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute
myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently …

Chemotherapy-induced neutropaenia is a major risk factor for infection-related morbidity
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …

Purpose To assess the clinical outcome and the influence of biomarkers associated with
apoptosis inhibition (Bcl-2), tumor proliferation (MIB-1), and cellular differentiation on the …

The Lunenburg Lymphoma Biomarker Consortium (LLBC) evaluated the prognostic value of
IHC biomarkers in a large series of patients with diffuse large B-cell lymphoma (DLBCL) …

Purpose To evaluate the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome
(MDS) and overall mortality in patients receiving chemotherapy with or without granulocyte …

Updated international guidelines published in 2006 have broadened the scope for the use
of granulocyte colony-stimulating factor (G-CSF) in supporting delivery of myelosuppressive …

Background Patients treated for non-Hodgkin lymphoma are at risk of cardiovascular
adverse events, with the risk of heart failure being particularly high. A regimen of …

Abstract Background Adult Langerhans cell histiocytosis (LCH) is a rare disease. The
combination of vinblastine and prednisone, given in a 6-month course, is the standard of …

Non-Hodgkin lymphoma (NHL) is a relatively common type of cancer in children and
adolescents and young adults (AYA). 1, 2 The most prevalent histological subtypes …